Interpace Q1 revenue $10.3M (+4% YoY); income from ops $0.6M; record test volume +10%

INTERPACE BIOSCIENCES, INC.

2024-Q1 EPS reported $0.11 revenue$10,273,000

Q1 net revenue $10.3M, up 4% YoY from $9.8M; test volume up 10% to record levels.
Income from continuing ops $0.6M vs $0.4M prior year; operating income $0.9M vs $0.7M.
Adjusted EBITDA $1.0M vs $1.2M prior year; gross margin 59% vs 61%.
Cash collections $10.2M; cash balance $2.8M at Mar 31, 2024, down from $5.6M due to $3.1M debt paydown.
Fifteenth consecutive quarter of YoY volume growth; CEO cites adoption of ThyGeNEXT, ThyraMIRv2, PancraGEN.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2024 results: revenue $10.3 million, net income $0.6 million.

Period: first quarter ended March 31, 2024
Revenue: $10.3 million
Net income: $0.6 million
Result: reported results

Exact text from the filing

stated in such filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces First Quarter 2024 Financial and Business Results ● Q1 Revenue of $10.3 million; a 4% increase year-over-year ● Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 9, 2024 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-018465

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.